This portal is a part of
Company Database with
  • 22'868 Companies
  • 23'652 Biotech / Medtech Products
  • 3'007 Financing rounds
  • 237 Company valuations
  • 27'605 Management details
  • 4'930 Licensing opportunities
Licensing Deals Database with
  • 1'378 Deals each with financial information
 
Latest Updates
Global Database

 

 

Events
  		• Feb 2012 - Zurich:
    6th Swiss-Scandinavian Bio-Business Seminar
  		• Mar 2012 - Haifa:
    BioInvest Israel 2012
  		• Mar 2012 - MUMBAI:
    USFDA & EU Essentials of Drug Safety and Pharmacovigilance -
    Add Event
    EVENTS IN THE LIFE SCIENCES INDUSTRY
    Add an Event
     
     
    6th Swiss-Scandinavian Bio-Business Seminar
    08.02.12
     
         		 SIX Stock Exchange building, Selnaustrasse 30  
    Zurich, Switzerland
    The 6th Swiss-Scandinavian Bio-Business Seminar is organized by the Nordic countries in cooperation with Swiss partners. During this high-level partnering and investor conference, Swiss and Nordic biotech and pharmaceutical companies as well as investors meet in one-to-one meetings and present themselves in plenum.

    The goal of the conference and by means of the Swiss-Nordic focus is to establish new contacts and networks.

    The conference has a broad focus within biotech and pharma (drug development, drug delivery, bio materials, medical device, diagnostics, contract manufacturing, CRO, etc.) and gathers small, early stage companies as well as global, commercial corporations.
      Event website
    Contact Mr. Hampus Nilzen
      E-mail
     
     
     
    BioInvest Israel 2012
    05.03.12 - 06.03.12
     
         		 Dan Carmel Haifa, Sderot HaNassi 85-87 
    Haifa, Israel
    BioInvest Israel 2012, is the international Gathering of the Investment & Corporate Communities with the Israeli Life Sciences industry.
    Organized in response to the growing demand for an efficient healthcare partnering forum where investors , Medtech and Biopharma companies can meet to talk business. BioInvest Israel 2012 provides private and public Medtech & Biopharma companies the opportunity to present and partner with an audience of investors and business development executives from Israel and abroad.

    In today's challenging market the Israeli Medtech & Biopharma industries are becoming ever more attractive to global companies and investors looking for successful ventures, Technologies, IP trade , Mergers , Acquisition, Investments or Exit opportunities that will increase the value of their firms.

    Join us at BioInvest Israel and learn about the innovative investing opportunities awaiting for you in Israel….
      Event website
    Contact Mr. Daniel Weisswasser
      E-mail
     
     
     
    USFDA & EU Essentials of Drug Safety and Pharmacovigilance -
    05.03.12 - 07.03.12
     
         		 TBD Hotel,MUMBAI 
    MUMBAI, India
    Overview: This training course is designed to give pharmaceutical and biologic companies operating in the U.S. and EU an understanding of product safety and regulatory compliance. The course will include case studies of adverse events to illustrate the decision-making process and reasoning needed behind when and how to properly report incidents to regulatory authorities.
    Product safety makes headlines every day - and the impact on a company’s image, consumer confidence, and Wall Street’s opinion is profound. While good safety data has historically been a prerequisite for product approval, recent media attention has intensified public and Congressional scrutiny and resulted in regulations such as the FDA Amendment Act and its strengthened requirements for monitoring post-marketing safety.
    Agenda:
    • Overview of Pharmacovigilance
    • Assessing Adverse Event Cases
    • Reporting Adverse Events
    • Global Regulatory Requirements
    • Inspections and Audits
    • Pharmacovigilance Best Practices
    • Preparing for an Inspection
    • Case Studies with Real-Life Inspection Findings
    • Background to Signal Detection
    • Signaling Exercises
    • Data Mining Exercises
    • Pharmacovigilance and Risk Management Process
    Who will benefit:
    • Drug safety and Pharmacovigilance
    • Regulatory affairs
    • Clinical development
    • Executives (including C-Level) with any Legal responsibility for drug safety
    • Clinical safety staff
    • Pharmacovigilance specialists
    • Regulatory affairs professionals
    • Quality management specialists
    • Management involved in clinical oversight
    • Pharmacovigilance
    • Pharmacoepidemiology
    • Regulatory affairs


    Steve Jolley, Principal, SJ Pharma Consulting
    Steve Jolley is a subject matter expert in all areas of global safety compliance and signal detection, and is a frequent speaker at leading industry events including DIA and MHRA. He has 25 Years’ experience in drug safety & Pharmacovigilance and has worked with over 50 clients in the US, Europe and Japan. He holds degrees in mathematics and computer science from Cambridge University, England. Steve is a featured speaker with FDA at DIA conferences and webinars on auditing, signaling and data mining. Steve began his career in the pharmaceutical industry in 1985 when he founded DLB Systems, a supplier of computer systems for clinical trials and adverse event reporting to many of the leading life science companies worldwide.

    DATE AND VENUE: Venue
    March 5th, 6th and 7th, 2012
    at Mumbai, INDIA
    Hotel: TBD
    Conference Timings: 9:00 am - 6:00 pm
      Event website
    Contact Mr. Event Coordinator
      E-mail
     
     
     
    Pharma-Biotech Product & Company Valuation
    18.03.12
     
         		 Novotel Amsterdam City , Europaboulevard 10 
    Amsterdam, The Netherlands
    By attending this course, you will:

    1. Know what determines the value of life science biotechs and emerging pharma companies.

    2. Gain a thorough understanding of key valuation terms, concepts, tools & techniques.

    3. Learn and practice how to:
    - Use a model that assesses the soft factors of a biotech company prior to its valuation.
    -Calculate the value of a biotech company.
    -Calculate the value of a development compound with an excel tool you can take home and use for any other pharmaceutical product in development.
    -Structure licensing deals between pharma and biotech, covering issues such as milestones and royalty payments.

    4. Gain expert insight and advice from Patrik Frei and Johan Ohlsson who have assessed and valued numerous products and companies in the life sciences industry.
      Event website
    Contact Mrs. Marie Stricklesse
      E-mail
     
     
     
    The 14th MedTech Investing Europe Conference
    19.03.12 - 20.03.12
     
         		 Montreux Convention and Music Centre 
    Lausanne, Switzerland
    This Conference will bring together innovators, leading investors and major healthcare corporations to uncover the latest challenges and opportunities within the medtech arena.

    Hear from the most influential experts:
    - Hélène Chevrou-Séverac, Global Head, Health Economics & Market Access, Nestlé Health Sciences, Switzerland
    - Herb Riband, Vice President External Affairs International, Medtronic International, Switzerland
    - Crispin Simon, Formerly CEO, BioCompatibles, UK
    - Laura Piccinini, President, Stryker Europe, Italy
    - Jans Keltjens, Chief Executive Officer, Endosense, Netherlands
    And many more…

    Invest in the best opportunities available in medtech:
    Over 30 medtech companies will showcase their latest innovations and investment opportunities in cardiovascular, imaging, diagnostics, orthopaedics and other sectors. In addition, one-to-one meetings will be held for you to discuss potential business opportunities and foster future relationships.

    This not-to-be-missed event will give you the opportunity to network in a private and relaxing setting.

    Exclusive offer for Venture Valuation contacts: 40% discount is offered to all contacts on delegate packages.

    If you require further information please visit www.medtechinvesting.com and to book your place, please contact Kekeli Sodji at kekelisodji@campden.com and quote ‘VV’.
      Event website
    Contact Mrs. Kekeli Sodji
      E-mail
     
     
     
    BioEuropeSpring
    19.03.12 - 21.03.12
     
         		 RAI convention Center 
    Amsterdam, Netherlands
    BIO-Europe Spring® is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities.

    Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.
      Event website
     
     
     
    Life Science Investment Day Scandinavia 2012
    27.03.12
     
         		 Hilton Malmö City 
    Malmö , Sweden
    SwedenBIO and Partners proudly present Life Science Investment Day Scandinavia 2012 - a dynamic arena where top international investors, life science professionals and stakeholders from regions with strong growth and development meet the best Life Science investment and business opportunities Scandinavia has to offer.

    Our goal is to stimulate the growth and prosperity of Scandinavian Life Science by facilitating more investment, collaboration, partnerships and mergers & acquisition in the region.

    Tuesday March 27, 2012, Hilton Malmö City, Sweden. 8.00 – 17.00 followed by social event For registration, please see www.swedenbio.com/Life-Science-Investment-Day-Scandinavia
      Event website
    Contact Mr. Jonas Ekstrand
      E-mail
     
     
     
    BIOINITALY INVESTMENT FORUM & INTESA SP START-UP INITIATIVE
    18.04.12 - 19.04.12
     
         		 Palazzo Besana, Piazza Belgioioso 1 
    Milano, Italy
    BioInItaly is an event that brings together biotech companies and investors. On a yearly basis Assobiotec, together with Innovub SSI and Intesa Sanpaolo Start-Up Initiative, organizes a highly innovative end-to-end process aimed at scounting start-ups and facilitating financing rounds as well as closing business agreements in the biotech field.
      Event website
    Contact Mr. Mario Bonaccorso
      E-mail
    Further information Details
     
     
     
    The Pharmaceutical Out-licensing Course
    26.04.12 - 27.04.12
     
         		 Sheraton Brussels Airport Hotel 
    Brussels, Belgium
    By attending this course, you will:

    1 Understand the key factors leading to a successful out-licensing deal of pharmaceutical compounds in R&D.
    2 Learn how to profile your product and prepare product information to maximize its attractiveness to third parties.
    3 Understand the key factors leading to valuing your product and how to set up a spreadsheet to optimise the commercial structure of the deal.
    4 Find out how to target potential partners - and the best way to make successful contacts.
    5 Learn what to include in a term sheet, as well as in CDAs and MTAs, and which issues to watch out for during negotiations.
    6 Understand the due diligence process and what will be expected from you.
    7 Get expert advice on negotiation strategy and on managing a deal post-signature.
      Event website
    Contact Mrs. Annelies Swaan
      E-mail
     
     
     
    The Pharma Business Development Course
    04.06.12 - 05.06.12
     
         		 Hilton Zurich Airport Hotel 
    Zurich, Switzerland
    By attending this course, you will:

    1 Grasp the entire process of deal-making within the pharmaceutical and biotech industries, and learn the language, the concepts and tools from a practitioner’s point of view.
    2 Know how to profile the most suitable products for your company’s profile, and where to search for the opportunities.
    3 Grasp the principles of valuation and know what works best for which purpose.
    4 Get expert advice on negotiation strategy and tools, and on how to best conduct the interactions.
    5 Learn what makes up a good term sheet and how to assess those from other parties.
    6 Know how to best manage the contract phase and how to avoid the financial and legal pitfalls that can break a deal.
    7 Capitalize on Martin Austin’s vast experience in concluding and financing successful deals in the pharma and life science biotech industries.
      Event website
    Contact Mrs. Annelies Swaan
      E-mail
     
     
     
    The Pharma Business Development Course
    04.10.12 - 05.10.12
     
         		 Sheraton Brussels Airport Hotel 
    Brussels, Belgium
    By attending this course, you will:

    1 Grasp the entire process of deal-making within the pharmaceutical and biotech industries, and learn the language, the concepts and tools from a practitioner’s point of view.
    2 Know how to profile the most suitable products for your company’s profile, and where to search for the opportunities.
    3 Grasp the principles of valuation and know what works best for which purpose.
    4 Get expert advice on negotiation strategy and tools, and on how to best conduct the interactions.
    5 Learn what makes up a good term sheet and how to assess those from other parties.
    6 Know how to best manage the contract phase and how to avoid the financial and legal pitfalls that can break a deal.
    7 Capitalize on Martin Austin’s vast experience in concluding and financing successful deals in the pharma and life science biotech industries.
      Event website
    Contact Mrs. Annelies Swaan
      E-mail
     
     
     
    Pharma-Biotech Product & Company Valuation
    24.10.12
     
         		 Hilton Zurich Airport Hotel, Hohenbuehlstrasse 10 
    Opfikon-Glattbrugg, Switzerland
    By attending this course, you will:

    1. Know what determines the value of life science biotechs and emerging pharma companies.

    2. Gain a thorough understanding of key valuation terms, concepts, tools & techniques.

    3. Learn and practice how to:
    -Use a model that assesses the soft factors of a biotech company prior to its valuation.
    -Calculate the value of a biotech company.
    -Calculate the value of a development compound with an excel tool you can take home and use for any other pharmaceutical product in development.
    -Structure licensing deals between pharma and biotech, covering issues such as milestones and royalty payments.

    4. Gain expert insight and advice from Patrik Frei and Johan Ohlsson who have assessed and valued numerous products and companies in the life sciences industry.
      Event website
    Contact Mrs. Marie Stricklesse
      E-mail
     
     
     
    The Pharmaceutical Out-licensing Course
    25.10.12 - 26.10.12
     
         		 Hilton Zurich Airport Hotel 
    Zurich, Switzerland
    By attending this course, you will:

    1 Understand the key factors leading to a successful out-licensing deal of pharmaceutical compounds in R&D.
    2 Learn how to profile your product and prepare product information to maximize its attractiveness to third parties.
    3 Understand the key factors leading to valuing your product and how to set up a spreadsheet to optimise the commercial structure of the deal.
    4 Find out how to target potential partners - and the best way to make successful contacts.
    5 Learn what to include in a term sheet, as well as in CDAs and MTAs, and which issues to watch out for during negotiations.
    6 Understand the due diligence process and what will be expected from you.
    7 Get expert advice on negotiation strategy and on managing a deal post-signature.
      Event website
    Contact Mrs. Annelies Swaan
      E-mail
     
     
     
    The Pharma Business Development Course
    12.12.12 - 13.12.12
     
         		 Radisson Edwardian Heathrow  
    London, UK
    By attending this course, you will:

    1 Grasp the entire process of deal-making within the pharmaceutical and biotech industries, and learn the language, the concepts and tools from a practitioner’s point of view.
    2 Know how to profile the most suitable products for your company’s profile, and where to search for the opportunities.
    3 Grasp the principles of valuation and know what works best for which purpose.
    4 Get expert advice on negotiation strategy and tools, and on how to best conduct the interactions.
    5 Learn what makes up a good term sheet and how to assess those from other parties.
    6 Know how to best manage the contract phase and how to avoid the financial and legal pitfalls that can break a deal.
    7 Capitalize on Martin Austin’s vast experience in concluding and financing successful deals in the pharma and life science biotech industries.
      Event website
    Contact Mrs. Annelies Swaan
      E-mail
     
     
    © 2012 Venture Valuation  |  Terms of Use & Privacy Policy  |  Print this page